Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.0K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.0K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.2K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.2K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

678
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
678
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

739
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
739

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding Statistical Noise in Research: 2. Noise in Clinical Trials and Observational Studies.

Indian journal of psychological medicine·2023
Same author

Prevalence of Bedtime Procrastination in University Students and Reexamination of the Bedtime Procrastination Scale.

The primary care companion for CNS disorders·2023
Same author

Publication of studies registered in Clinical Trials Registry of India: An audit of mood disorder research protocols from 2009-2019.

Indian journal of psychiatry·2023
Same author

Neuroleptic Malignant Syndrome with Low Dose Lithium, Without Concomitant Antipsychotics.

Indian journal of psychological medicine·2023
Same author

Understanding Statistical Noise in Research: 1. Basic Concepts.

Indian journal of psychological medicine·2023
Same author

Survival of Combined Overdose with Very High Doses of Clozapine and Blonanserin: A Case Report.

Indian journal of psychological medicine·2023

Related Experiment Video

Updated: Apr 22, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

739

Antidepressant augmentation with anti-inflammatory agents.

Chittaranjan Andrade1

  • 1Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India candrade@psychiatrist.com.

The Journal of Clinical Psychiatry
|October 9, 2014
PubMed
Summary
This summary is machine-generated.

Nonsteroidal anti-inflammatory drugs (NSAIDs) show potential for augmenting antidepressant treatment in major depressive disorder. However, evidence for efficacy in treatment-resistant depression is lacking, and safety concerns remain.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.8K
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

2.2K

Related Experiment Videos

Last Updated: Apr 22, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

739
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.8K
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

2.2K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Depression treatment often requires augmentation strategies for non-responsive patients.
  • Neuroinflammation is a potential mechanism in depression.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) show promise in animal models for depression and augmentation therapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of NSAID augmentation in major depressive disorder.
  • To examine the current evidence for NSAID use in antidepressant-resistant depression.

Main Methods:

  • Review of randomized controlled trials (RCTs) and observational studies.
  • Analysis of data on celecoxib augmentation in major depressive disorder.
  • Consideration of adverse events and drug interactions.

Main Results:

  • Four small RCTs (N=160) suggest celecoxib augmentation may improve short-term outcomes in major depressive disorder.
  • Human observational studies on NSAIDs for depression have yielded mixed results.
  • No data currently support NSAID use in antidepressant-resistant depression.

Conclusions:

  • NSAID augmentation is a tentative approach for nonrefractory major depressive disorder.
  • Further research is needed to establish the safety and efficacy of NSAIDs in depression treatment.
  • Concerns regarding adverse events and drug interactions with serotonin reuptake inhibitors warrant caution.